These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1110 related articles for article (PubMed ID: 28139422)
1. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation. Baumann BC; Baumann JC; Christodouleas JP; Soffen E Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422 [TBL] [Abstract][Full Text] [Related]
2. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy. Rutenberg MS; Meister M; Amin PP; Hussain A; Naslund MJ; Kwok Y Brachytherapy; 2016; 15(6):722-729. PubMed ID: 27693225 [TBL] [Abstract][Full Text] [Related]
3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer. Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133 [TBL] [Abstract][Full Text] [Related]
5. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Chen CP; Weinberg V; Shinohara K; Roach M; Nash M; Gottschalk A; Chang AJ; Hsu IC Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):324-9. PubMed ID: 23474112 [TBL] [Abstract][Full Text] [Related]
6. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
7. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119 [TBL] [Abstract][Full Text] [Related]
9. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527 [TBL] [Abstract][Full Text] [Related]
10. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404 [TBL] [Abstract][Full Text] [Related]
11. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973 [TBL] [Abstract][Full Text] [Related]
12. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Lee HK; Adams MT; Motta J Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939 [TBL] [Abstract][Full Text] [Related]
13. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy? Morris LM; Izard MA; Wan WY Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524 [TBL] [Abstract][Full Text] [Related]
14. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039 [TBL] [Abstract][Full Text] [Related]
15. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
17. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952 [TBL] [Abstract][Full Text] [Related]
18. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254 [TBL] [Abstract][Full Text] [Related]
19. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. Wong WW; Buskirk SJ; Schild SE; Prussak KA; Davis BJ J Urol; 2006 Nov; 176(5):2020-4. PubMed ID: 17070243 [TBL] [Abstract][Full Text] [Related]
20. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]